GIANT NEUROFIBROMA AND SURGICAL CORRECTION: CASE REPORT
Keywords:
Neurofibroma, Neurofibromatoses, Neurofibroma olexiformAbstract
Neurofibromatosis is a heterogeneous group of hereditary cancer syndromes, type 1 represents 96% of cases, and the most common form of clinical presentation is café au lait spots. Plexiform neurofibromas may also be present. Currently, complete resection is the only curative treatment option, however, it becomes challenging in the case of giant lesions. The objective of this study was to report the case of a patient with giant neurofibroma and to discuss its clinical and pathological aspects, as well as to demonstrate the surgical treatment. The patient presented plexiform tumors with large dimensions in the abdomen and thighs, with several resections over the years. In the reported surgical procedure, a large part of the tumor was removed and the segment was reconstructed afterwards. Although surgical removal is the standard for the treatment of these tumors, the result is not always satisfactory, propeling the search for new techniques and complementary therapies.
References
Kresak J, Walsh M. Neurofibromatosis: A Review of NF1, NF2, and Schwannomatosis. Journal of Pediatric Genetics. 2016 Mar 9;05(02):098–104.
Fisher MJ, Shih CS, Rhodes SD, Armstrong AE, Wolters PL, Dombi E, et al. Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial. Nature Medicine. 2021 Jan 1;27(1):165–73.
Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nature Reviews Disease Primers. 2017 Feb 23;3.
Azizi AA, Slavc I, Theisen BE, Rausch I, Weber M, Happak W, et al. Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [18F]FDG-PET imaging. Is it of value in asymptomatic patients? Pediatric Blood and Cancer. 2018 Jan 1;65(1).
Rosset C, Vairo F, Cristina Bandeira I, Fonini M, Netto CBO, Ashton-Prolla P. Clinical and molecular characterization of neurofibromatosis in southern Brazil. Expert Review of Molecular Diagnostics. 2018 Jun 3;18(6):577–86.
Wei G, Farooq J, Kumar A. Impact of mind-body treatment interventions on quality of life in neurofibromatosis patients: A systematic review and meta-analysis. Vol. 34, Dermatologic Therapy. Blackwell Publishing Inc.; 2021.
Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in Children with Inoperable Plexiform Neurofibromas. New England Journal of Medicine. 2020 Apr 9;382(15):1430–42.
Choi J, An S, Lim SY. Current concepts of neurofibromatosis type 1: pathophysiology and treatment. Archives of Craniofacial Surgery [Internet]. 2022 Feb 20;23(1):6–16. Available from: http://e-acfs.org/journal/view.php?doi=10.7181/acfs.2022.00633
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Arquivos Catarinenses de Medicina
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
